Equities analysts predict that Kindred Biosciences Inc. (NASDAQ: KIN) will announce a profit of ($ 0.40) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for the Kindred Biosciences revenue, with the highest EPS estimate coming in ($ 0.38) and the lowest estimate coming in ($ 0.42). Kindred Biosciences reported a profit of ($ 0.29) per share in the same quarter of last year, indicating a negative year-on-year growth of 37.9%. The company is scheduled to publish the results of its quarterly results on Tuesday, November 6.
According to Zacks analysts expect that Kindred Biosciences will report an annual profit of ($ 1.51) per share for the current year, with EPS estimates ranging from ($ 1.56) to ($ 1.44). For the following year, analysts expect the company to report a profit of ($ 1.22) per share, with EPS estimates ranging from ($ 1.37) to ($ 1.04). The EPS calculations by Zacks Investment Research are an average based on a survey of research analysts related to Kindred Biosciences.
Kindred Biosciences (NASDAQ: KIN) published its quarterly results for the last time on Thursday, August 9th. The biopharmaceutical company reported ($ 0.39) Earnings per Share (EPS) for the quarter, with consensus analysts' estimates missing ($ 0.38) with ($ 0.01).
A number of analysts recently issued reports about the stock. HC Wainwright repeated a "buy" rating and set a $ 16.00 price target on Kindred Biosciences shares in a report on Monday, August 13. Zacks Investment Research has upgraded the Kindred Biosciences shares from a & # 39; hold & # 39; credit to a & # 39; buy & # 39; credit and a target price of $ 15.00 for the company in a study letter on Wednesday, July 25. On Tuesday, August 7, LADENBURG THALM / SH SH downgraded a downgraded stock of Kindred Biosciences from a "buy" rating to a "neutral" rating in a research note. Lake Street Capital started coverage on Kindred Biosciences shares in a study letter on Monday 23 July. They gave a "buy" score for the company. Finally, Cantor Fitzgerald started the coverage on Kindred Biosciences shares in a study letter on Monday 23 July. They gave an "overweight" rating and a target price of $ 20.00 for the company. Three equity research analysts have rated the shares with a hold rating, seven have issued a buy-rating and two have a strong buy-rating for the company's shares. The company has an average rating of & # 39; Buy & # 39; and an average price target of $ 16.75.
In other news: major shareholder Park West Asset Management Llc acquired 845,262 shares in the Kindred Biosciences portfolio in a transaction that took place on Wednesday 20 June. The stock was purchased at an average price of $ 9.50 per share, with a total value of $ 8,029,989.00. The purchase has been disclosed in a legal application to the Securities & Exchange Commission, which is available through this link. Insider Richard Chin also sold 40,000 shares of the company's shares in a transaction that took place on Wednesday, August 1. The shares were sold at an average price of $ 13.51, for a total transaction of $ 540,400.00. After the transaction, the insider now owns 2,106,071 shares of the company's shares, valued at approximately $ 28,453,019.21. The information for this sale can be found here. Insiders sold 132,610 shares of company shares worth $ 1,482,900 in the last quarter. Business mixers own 15.96% of the company's shares.
Large investors have recently changed their positions in the shares. Metropolitan Life Insurance Co. NY bought a new position in Kindred Biosciences in the second quarter with a value of approximately $ 103,000. Tower Research Capital LLC TRC lowered its position in Kindred Biosciences by 764.3% in the second quarter. Tower Research Capital LLC TRC now holds 9,671 shares in the share capital of the biopharmaceutical company worth $ 103,000 after purchasing an additional 8,552 shares in the last quarter. Paloma Partners Management Co acquired a new stake in Kindred Biosciences in the second quarter with a value of approximately $ 119,000. MetLife Investment Advisors LLC acquired a new stake in Kindred Biosciences in the second quarter, with a value of approximately $ 146,000. Finally, Citadel Advisors LLC acquired a new stake in Kindred Biosciences in the second quarter, worth around $ 218,000. 56.85% of the shares are held by institutional investors.
NASDAQ KIN opened on Friday at $ 14.85. Kindred Biosciences has a low of 52 weeks of $ 6.80 and a height of 52 weeks of $ 15.75. The stock has a market capitalization of $ 500.24 million, a P / E ratio of -12.07 and a beta of 0.28.
Kindred Biosciences Company profile
Kindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The product pipeline of the company includes small molecules and biological drugs for a range of indications in dogs, cats and horses. The main product candidates are Zimeta, a dipyron injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.
Read more: What is a rate?
Receive a free copy of the Zacks research report on Kindred Biosciences (KIN)
Visit Zacks.com for more information about research offers from Zacks Investment Research
Receive news and reviews for Kindred Biosciences Daily – Enter your email address below to receive a concise, daily summary of the latest news and analyst reviews for Kindred Biosciences and related companies with the FREE daily email newsletter from MarketBeat.com.